BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs February 26, 2024
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer February 26, 2024
Radiomedix and Orano Med Initiate Ph 2 Multi-Center Trial of Alphamedix™ for Targeted Alpha-Emitter Therapy of Neuroendocrine Cancers February 26, 2024
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Ph 3 Head and Neck Cancer Study February 26, 2024
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates February 26, 2024
Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program February 26, 2024
LAVA Therapeutics Announces Collaboration with Merck to Evaluate LAVA-1207 in Combination with KEYTRUDA January 31, 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs January 31, 2024
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers January 25, 2024
Accurus Biosciences and ImmPACT Bio Enter into an Exclusive Global License Agreement for a Potentially Best-in-Class CLDN18.2 Antibody January 25, 2024
Ferring announces full availability of ADSTILADRIN® (nadofaragene firadenovec -vncg) in the U.S. January 25, 2024
AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies January 18, 2024
Boehringer Ingelheim And 3T Biosciences Enter Into A Second Partnership To Develop Next-Generation Cancer Immunotherapies January 10, 2024
Orion and MSD Announce Initiation of Two Ph 3 Trials of ODM-208/MK5684 in Certain Patients with Metastatic CRPC January 10, 2024
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma January 10, 2024
Innate Pharma Announces Licensing Of A Fourth Natural Killer Cell Engager In Oncology To Sanofi January 10, 2024
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics January 10, 2024
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio January 10, 2024
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases January 10, 2024
Merck to Acquire Harpoon Therapeutics, including HPN328 in certain patients with small cell lung cancer and neuroendocrine tumors January 10, 2024
